What drove the share drop in 4543.T stock after the Q3 report?

Shares fell despite a Q3 beat because investors focused on tariff remarks and near-term headwinds. The stock closed **JPY 2010.50** on higher volume, showing profit-taking even with raised FY26 guidance.

How does Terumo’s valuation compare for 4543.T stock?

Terumo trades at PE **23.39** with EPS **88.49** and PB around **2.12**. Valuation sits near sector norms for medical instruments, reflecting steady margins and strong cash generation.

What is Meyka AI’s price forecast for 4543.T stock and the implied upside?

Meyka AI's forecast model projects a yearly price of **JPY 2786.67**, implying upside of **38.61%** versus current **JPY 2010.50**. Forecasts are model-based projections and not guarantees.

Should investors treat 4543.T stock as growth or defensive exposure?

Terumo blends growth and defensive traits. Its medical consumables create stable revenue, while Cardiac & Vascular innovations drive growth. Risk from tariffs and inventory cycles keeps the tone cautious.

JP Stocks

Terumo (4543.T JPX) Q3 beats, shares close JPY 2010.50: FY26 guidance raised

ByHuzaifa Zahoor February 13, 2026February 13, 2026

We saw Terumo Corporation (4543.T stock) report stronger third-quarter results on 13 Feb 2026, yet shares closed lower. The stock finished at JPY 2010.50, down 4.81% on heavy volume of 15,118,800 shares as investors weighed tariffs and near-term headwinds against raised FY26 guidance. Terumo raised revenue and profit guidance for the year, a key reason we keep the company on analysts’ radar for Healthcare exposure on the JPX in Japan.